Search scope:
排序: Display mode:
Jingqing Hu, Jie Qiao, Deying Kang, Baoyan Liu
Frontiers of Medicine 2011, Volume 5, Issue 2, Pages 203-207 doi: 10.1007/s11684-011-0138-6
Keywords: traditional Chinese therapeutics feature statistic
Developing macromolecular therapeutics: the future drug-of-choice
Huining HE, Victor C. YANG, Weibing DONG, Junbo GONG, Jingkang WANG,
Frontiers of Chemical Science and Engineering 2010, Volume 4, Issue 1, Pages 10-17 doi: 10.1007/s11705-009-0291-5
Keywords: worldwide challenging effective macromolecular self-owned intellectual
Human monoclonal antibodies as candidate therapeutics against emerging viruses
Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying
Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 462-470 doi: 10.1007/s11684-017-0596-6
The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
Keywords: human monoclonal antibodies emerging infectious diseases SARS-CoV MERS-CoV Ebola virus
Yu Wang, Lan Li, Yuanjiang Pan, Yu He, Zuhua Chen, Yunhao Xun, Yuhan Xu, Yilei Guo, Jiehong Yang, Jianchun Guo, Haitong Wan
Frontiers of Medicine 2021, Volume 15, Issue 4, Pages 629-637 doi: 10.1007/s11684-020-0825-2
Keywords: COVID-19 cardio-cerebrovascular disease traditional Chinese medicine clinical features clinical therapeutics
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 689-700 doi: 10.1007/s11684-020-0759-8
Keywords: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy
Frontiers of Agricultural Science and Engineering 2021, Volume 8, Issue 4, Pages 603-622 doi: 10.15302/J-FASE -2021397
Molecular engineering of dendrimer nanovectors for siRNA delivery and gene silencing
Yu Cao, Xiaoxuan Liu, Ling Peng
Frontiers of Chemical Science and Engineering 2017, Volume 11, Issue 4, Pages 663-675 doi: 10.1007/s11705-017-1623-5
Keywords: gene therapy RNAi therapeutics dendrimer nanovectors gene silencing
Enhanced penetration strategies for transdermal delivery
Qiaofei Pan, Yinglin Yu, Dong Chen, Genlong Jiao, Xiaowen Liu
Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 3, Pages 378-388 doi: 10.1007/s11705-019-1913-1
Keywords: transdermal delivery stratum corneum enhanced penetration therapeutics
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, Lanjuan Li
Frontiers of Medicine 2020, Volume 14, Issue 5, Pages 664-673 doi: 10.1007/s11684-020-0810-9
Keywords: coronavirus disease 2019 (COVID-19) mesenchymal stem cell acute respiratory distress syndrome stem cell therapeutics
Jiajia Chen, Chenxia Hu, Lijun Chen, Lingling Tang, Yixin Zhu, Xiaowei Xu, Lu Chen, Hainv Gao, Xiaoqing Lu, Liang Yu, Xiahong Dai, Charlie Xiang, Lanjuan Li
Engineering 2020, Volume 6, Issue 10, Pages 1153-1161 doi: 10.1016/j.eng.2020.02.006
H7N9 viruses quickly spread between mammalian hosts and carry the risk of human-to-human transmission, as shown by the 2013 outbreak. Acute respiratory distress syndrome (ARDS), lung failure, and acute pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was used to treat H7N9-induced ARDS in 2013. The transplant of MSCs into patients with H7N9-induced ARDS was conducted at a single center through an open-label clinical trial. Based on the principles of voluntariness and informed consent, 44 patients with H7N9-induced ARDS were included as a control group, while 17 patients with H7N9-induced ARDS acted as an experimental group with allogeneic menstrual-blood-derived MSCs. It was notable that MSC transplantation significantly lowered the mortality of the experimental group, compared with the control group (17.6% died in the experimental group while 54.5% died in the control group). Furthermore, MSC transplantation did not result in harmful effects in the bodies of four of the patients who were part of the five-year follow-up period. Collectively, these results suggest that MSCs significantly improve the survival rate of H7N9-induced ARDS and provide a theoretical basis for the treatment of H7N9-induced ARDS in both preclinical research and clinical studies. Because H7N9 and the coronavirus disease 2019 (COVID-19) share similar complications (e.g., ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.
Keywords: Mesenchymal stem cell Epidemic Influenza A Acute respiratory distress syndrome COVID-19 Stem cell therapeutics
Title Author Date Type Operation
Analysis on the distinguishing features of traditional Chinese therapeutics and related statistical issues
Jingqing Hu, Jie Qiao, Deying Kang, Baoyan Liu
Journal Article
Developing macromolecular therapeutics: the future drug-of-choice
Huining HE, Victor C. YANG, Weibing DONG, Junbo GONG, Jingkang WANG,
Journal Article
Human monoclonal antibodies as candidate therapeutics against emerging viruses
Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying
Journal Article
Comparison of the clinical features and therapeutics of COVID-19 in cardio-cerebrovascular disease (CCVD
Yu Wang, Lan Li, Yuanjiang Pan, Yu He, Zuhua Chen, Yunhao Xun, Yuhan Xu, Yilei Guo, Jiehong Yang, Jianchun Guo, Haitong Wan
Journal Article
ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC REVIEW
Journal Article
Molecular engineering of dendrimer nanovectors for siRNA delivery and gene silencing
Yu Cao, Xiaoxuan Liu, Ling Peng
Journal Article
Enhanced penetration strategies for transdermal delivery
Qiaofei Pan, Yinglin Yu, Dong Chen, Genlong Jiao, Xiaowen Liu
Journal Article
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, Lanjuan Li
Journal Article
Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment
Jiajia Chen, Chenxia Hu, Lijun Chen, Lingling Tang, Yixin Zhu, Xiaowei Xu, Lu Chen, Hainv Gao, Xiaoqing Lu, Liang Yu, Xiahong Dai, Charlie Xiang, Lanjuan Li
Journal Article